|
|
 |
|
By:
Matthias Augustin et al.
Courtesy Weleda USA
Long-term Adjuvant Treatment of Primary Intermediate to High-Risk Malignant Melanoma. By Matthias Augustin et al.
Category: Cancer and Iscador
Published by Arzneim.-Forsch./Drug Research on 1/1/2005
Summary:
A long-term Iscador treatment in patients with mean- to high-risk
primary malignant melanoma appears to be safe. A tumor enhancement was
not observed. In comparison with an untreated parallel control group
from the same cohort the results of the mistletoe treatment show a
significant survival advantage in the UICC-/AJCC stages II-III.
Read full article (.PDF format)
|
|
|
|